Durability of glycaemic efficacy over 2years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1111-1120

  Nauck, M A ^a   Del Prato, S ^b   Duran Garcia S ^c   Rohwedder, K ^d   Langkilde, A M ^e   Sugg, J ^d   Parikh, S J ^d  

^a Diabetes Centre   (Germany)

^b UNIVERSITY OF PISA   (Italy)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d ASTRAZENECA   (United Kingdom)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Phase III study; Randomised trial; SGLT2 inhibitor; Sulphonylureas; Type 2 diabetes; Weight loss therapy

Indexed keywords

DAPAGLIFLOZIN; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADD ON THERAPY; ADULT; AORTA ANEURYSM; ARTICLE; BLADDER STONE; CONSTIPATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY OCCLUSION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DEHYDRATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EDEMA; EPIGASTRIC PAIN; FATIGUE; FEMALE; FRACTURE; GENITAL TRACT INFECTION; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERHIDROSIS; HYPOGLYCEMIA; HYPOTENSION; HYPOVOLEMIA; LIMB PAIN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYCOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS CARCINOMA; PROSTATE CANCER; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION; UROLITHIASIS; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; BODY WEIGHT; CHEMICALLY INDUCED; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLIPIZIDE; GLUCOSIDES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; REPRODUCTIVE TRACT INFECTIONS; TREATMENT OUTCOME; URINARY TRACT INFECTIONS;

EID: 84914144323     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12327     Document Type: Article

References (39)

1. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
2. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 2012; 35: 1364-1379.
3. Alvarez Guisasola F, Mavros P, Nocea G, Alemao E, Alexander CM, Yin D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Diabetes Obes Metab 2008; 10(Suppl. 1): 8-15.
4. Cook MN, Girman CJ, Stein PP, Alexander CM. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 2007; 24: 350-358.
5. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia 2002; 45: S23-28.
6. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
7. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011; 65: 314-322.
8. Campbell RK. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing insulin-based therapy. Am J Manag Care 2012; 18: S55-61.
9. Nau DP. Recommendations for improving adherence to type 2 diabetes mellitus therapy-focus on optimizing oral and non-insulin therapies. Am J Manag Care 2012; 18: S49-54.
10. Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-1729.
11. Meng W, Ellsworth BA, Nirschl AA et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008; 51: 1145-1149.
12. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009; 85: 513-519.
13. Komoroski B, Vachharajani N, Boulton D et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009; 85: 520-526.
14. Rohwedder K, Hruba V, Salsali S et al. Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has a low propensity to cause hypoglycemia in patients with type 2 diabetes. Diabetes 2011; 60(Suppl. 1): A286.
15. Bolinder J, Ljunggren O, Kullberg J et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
16. Woo V, Langkilde AM, Sugg J, Parikh S. Abstract 9520: dapagliflozin, a novel antihyperglycemic agent that promotes urinary glucose excretion, reduces systolic blood pressure in patients with type 2 diabetes mellitus. Circulation 2011; 124: A9520.
17. Nauck MA, Del Prato S, Meier JJ et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
19. Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in type 2 diabetes. Diabet Med 2002; 19: 465-469.
20. Zhang M, Tsiatis AA, Davidian M. Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 2008; 64: 707-715.
21. Ptaszynska A, Johnsson KM, Apanovitch AM, Sugg JE, Parikh SJ, List JF. Safety of dapagliflozin in clinical trials for T2DM [abstract 1011-P]. Diabetes 2012; 61(Suppl. 1): A258.
22. Goke B, Lubben G, Bates PC. Coefficient of beta-cell failure in patients with type 2 diabetes treated with pioglitazone or acarbose. Exp Clin Endocrinol Diabetes 2004; 112: 115-117.
23. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010; 64: 1619-1631.
24. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010; 64: 562-576.
25. Matthews DR, Dejager S, Ahren B et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab 2010; 12: 780-789.
26. Cefalu WT, Leiter LA, Yoon K-H et al. Canagliflozin (CANA) Demonstrates Durable Glycemic Improvements Over 104 Weeks versus Glimepiride (GLIM) in Subjects With Type 2 Diabetes Mellitus (T2DM) on Metformin (MET) [Abstract 65-LB]. 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL, USA, June 21-25, 2013. Available from URL: http://diabetes.diabetesjournals.org/content/suppl/2013/06/21/62.Supplement_1.DC1/2013-Late-Breaking-Abstracts.pdf. Accessed 26 June 2013.
27. Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM. Trends in the prescription of anti-diabetic medications in the united kingdom: a population-based analysis. Pharmacoepidemiol Drug Saf 2009; 18: 973-976.
28. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.
29. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
30. Qaseem A, Humphrey LL, Sweet DE, Starkey M, Shekelle P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American college of physicians. Ann Intern Med 2012; 156: 218-231.
31. Ferrannini E, Jimenez Ramos S, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010; 33: 2217-2224.
32. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
33. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
34. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
35. Wilding JP, Norwood P, T'Joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009; 32: 1656-1662.
36. Wilding JP, Woo V, Soler NG et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med 2012; 156: 405-415.
37. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin 2012; 28: 1173-1178.
38. Rosenstock J, Aggarwal N, Polidori D et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-1238.
39. AstraZeneca and Bristol-Myers Squibb. Dapagliflozin Summary of Product Characteristics (SmPC) 2013. Available from URL: http://www.forxiga.eu/Forxiga%20Summary%20of%20Product%20Characteristics_SmPC_.pdf. Accessed 26 June 2013.